everyone, with taken range for representing range. at midpoint revenue full on year, us the million to XX% our afternoon. year-over-year we this half $XX joining to the We million the outlook together you, expect XXXX, first Based second our in for with of increasing in revenue, $X results, and quarter million XX% the remainder prior of thank be with the in Thanks, year-over-year $XX the Carrie, year ended growth and the quarter. line of for now
year firmly underlying believe opportunity for slower previous in will technology. our growth than proteomics market While be our significant a line this top expectations, we
the change of trajectory to potential the has proteomics. quo and technology Our status
changing takes status the quo However, time.
and what our opportunity us is in to have of confidence continue the offering I and product full the of differentiated of vision to boundaries push possible. to our capture the strength ahead
Just product, launched XT launch Proteograph the flagship Assay we second our after XX Proteograph of have the Kit, Kit. Assay months our
Thermo recently expanded using enable Astral newly Scientific our to Center, also with We or Spectrometer collaboration the the our with Proteograph Kit scale Assay in Fisher launched studies XT population launched combination Mass Orbitrap in Technology SEER STAC. Access recently
been about am than have more bullish opportunities our I today. I never
much foundation in While put for the continuing growth. work place pieces remains, we're to the long-term build to
products and walk to further new call seeing my we're becomes for to through our which them. as using our what this possible afternoon, actions On I will the exciting overcome data we're conviction well the that and customers, our new share will taking we're as more detail about I partners challenges commercial Proteograph Then near-term from experiencing some the validates Product Suite. adoption
burn our to results includes call Finally, in $XXX over recent investments. actions cash robust and which reduce further quarter sheet, cash David turn to provide our second equivalents and approximately preserve on the more details I will financial our cash, to our balance to million
studies will to the the powered generate said, that long Prior experiencing. of unbiased commercial discovery. were a a to content, have believe proteomics the we open in said, discovery. large-scale vast our currently leveraging to ability studies frontier very is adoption amounts we proteomic we new technology differentiated believe and high-performance That therefore product fuel underpowered Proteograph, and and we're As proteomics small between there our adequately up and disconnect versus
progress be will us, technologies disruptive linear. Similar to our new preceding commercial always not other
return are going over quickly make time. sure the we're highest efforts learning approach our result optimizing As we're focus and developing market, and to in the to
headwinds. we many we can in adoptions, that also and are the in a impact most the some this directly in market tackling current over way temporary quickly them. and them tailwinds months we headwinds While years see would and see commercial accelerate These coming market interrelated that we're
instruments, acquisition genomitists Most to the segment notably, a and a these use of that first, the of are: seen mass namely biologists be can mass to new customers and are spec for adoption as barrier the spec, [ph].
manner of a available to We're these our challenging macro in lower order technology. need publicly capital the commercial the environment terms value headwinds for barriers address taking in the created to And for has demonstrating additional an more biological new of a to finally, of decoding to to Second, and cycle. adoption. barriers temporary shorten data sales of disruptive unbiased availability publications, and steps the at Proteo in complex there's work scale
technology genomics So and biologists easier both data. what market across First, genomitists. making we're changes we is proteomics important to for and to access proteomics will always spec market. especially be our doing? are enable This said addressable that mass for the We've
While this that nuanced some behavioral customers adoption. our to market between us refine genomics drive proteomics there and remains case, differences approach development the to are requires
of spec their limited to deep had or scale a Consequently, studies. Proteomics customers samples. the previously or unbiased of store they have did need mass expert technological that maintain large not barriers core
on the for involve mass consumables. to the acquisition expenditures expenditures operations large and the capital relatively spectrometers small the prior Proteograph, Additionally, of and investments
As traditional value Suite. technology the the we're finding of Proteograph research proposition performing spec is Product mass proteomic a recognize that our result, readily
unbiased studies there's up secure average, on to to slower large-scale samples to ramp funding and they proteome the large-scale need studies. pursue since However,
Proteograph introduced operating budgets. generate the allow experts, to to To by the of SIPP begin barrier using them them to utilizing samples available to funding needed larger remove strategic right studies. This will placement secure the instrument the spec away the capital help have for conduct data and investment mass or program, we
approaches. scale universally their micro value experience to Conversely, the unbiased These generally biological with generating the better and very studies. large area of the approaches, biologists unbias and to are are to expenditures discovery given access conduct for almost for with genomics, OMEX are and of familiar relative consumable sample potential have customers genomes data research positioned exomes recognized targeted
mass that spec these spec they of and of to as the use discovery approach. powerful view acquisition and new many a appreciate the customers yet Proteograph's instrument adoption, We're unbiased the scalable finding to a potential mass barrier of potential
For provide these allows from the have we or customers, run in have now STAC, sample Proteograph and run to which Seer a to study samples lab the introduced data. Access spec Seer services or mass alternatively end-to-end Center user their own Technology
mass the their labs. important We Proteograph provided Suite, time, technologies by believe these insights Product the will, over spec customers to gain that to as apply and add and biological validate access they
top I our have to as develop the the Proteomics we Proteogenomics of Scientific Thermo at Importantly, Fisher call, and optimize expanded mentioned collaboration workflows. with and
will mass spec Thermo Scientific STAC primarily Orbitrap program, this of XT Fisher part Assay. services mass spectrometer astral Proteograph leveraging new provide by our along As with
and at still the technology. initial will unbiased already customers in at and the traction the available seeing rate this data Proteomics Proteograph can stimulate that increase and of improve demonstrating of that the depth This ramp While and scale the data believe early, it we're can velocity STAC positive our publicly our customers is stages use launch Suite. access the adopt publications, Product which very power STAC of will and
there publication, to shorten is proof sales customers' absence studies sales initiatives adopt end and time of it generally In because with currently where third-party sales build growing. year. and accounts, under to the cycle. are ones taking of relationships protracted the will still the correlated the review papers while the and we're base customer to of technology. is establish peer There the needed, additional The be takes cycle Second, that credibility are by cycle four new comfort is publication principle submitted are inversely with several
Product and available interest to a growing to the in see We us. opportunities number Suite Proteograph continue strong of
we Suite down increasing get awareness on through the our publications technology for doubling unique by third-party As breakthrough doing market on opportunities capabilities. nature and and customers to of potential us our meetings building creating KOLs Proteograph we're and in-person to for and know of the seminars. our We're domain, wait educating to customers Product technology its this the more public enter
understand customers papers support In sets continuing we're with proof help support publishing to of data customers and analyze in studies. development existing robust and of them and studies, new addition, our with principle potential these
in made to also commercial changes have and the recent leadership of regional both terms team, We managers. business
impact have While time the to it's in from in going on ahead. changes aggregate, place opportunity commercial in the see we I'm confident these deliver strategy our take to some and the to team
from the creative widely for especially solutions Finally, macro obtain from to hearing Product a customers that whose environment, not value they're prospective amidst proposition Suite. for technology Proteograph new the is disruptive customers cautious SIP Product We're we're purchasing this yet the the providing challenging through this, we're through peer through data access To demonstrated either address the accelerating insights offering customers utilization solutions to review biological Suite, stack. accelerating creative or through acquisition publications. Proteograph
These of data help this the the of scale. the instrument SIP, fact year. sets other with capital Product to rather SIP peer-reviewed provide seen for and earlier Through of may the thereby is customers when unique launch with presentations consumable and to a also also than an less to an scale. year potential ability and and operating purchase readily the accelerate we many adoption some coupled will initial cases publications by at funds these that since success exemplify This will its us through the to barriers potential our than more aided generation proof of unbiased customers access have a its good period at solution power Suite Reducing available proteomics Proteograph significant kits. of use loan program time, budgets. value budgets to to the provide customer insight already of typically We've
the in of the Society I mentioned June. call, the Spectrometry for early two at made at Mass American Conference As announcements we top important
Scientific. launch to the sample all to of compromising the uniquely Proteograph studies First, peptide more enabling than the spec types Proteograph XT access with time, than kit; mass species speed site, collaboration The scale of combination protium assay and X stack the provides hour enabling of to throughput with our the to of of unprecedented as launch XT assay workflow the design scale. insights customers studies Thermo performance, Fisher discovery. and large-scale scope, an allows less and the without diversity second, doubling of further high-resolution power XT The and proteomics expansion into at unbiased Proteograph sample level, with
This an and enormous vast our understanding on untapped health week. amount kit potential is the genomics more proteomics insights functional biological proteomics XT deepen accessible single for can The genomic operator with variants they per characterize researchers impact of of incredibly there access their discovered make exciting and content be a proteomic Proteograph yet samples since of as protium to even both and is And assay hundreds with makes a information. to disease.
Thermo The ASMS, Scientific combination Spectrometer for Astral discovery At automated over Proteograph performance IDs XX,XXX X% per in workflow rate. and proteomics the at an Astral Mass peptide produces XT of the combination exceptional of the Orbitrap® fully of and the Fisher unbiased Proteograph highlighted and unprecedented plasma the X,XXX the XT over of deep sample speed. a with Orbitrap IDs protein false scale
The multiple this and discussions of were prior paved unbiased regarding population-scale Proteograph speed impossible the for scale, depth, way unprecedented demonstration to which the has to studies XT. contemplate proteomic
possible will begin As access what the the we proteomic flywheel to have years even we level iceberg the unbiased two we breadth from will of X, in the think The information XX, content at the depth demonstrated now. unparalleled will prospective is space just and of accelerate. be tip of customers today believe readily value studies, be compared this the to will and of or
in this The of first of customer accelerate. see to to what the period starting studies signs we of year in beginning saw customer-driven we the number has same last from year. doubled half We're these studies saw
early seeing Proteograph insights, Importantly, capabilities impact incredible expanded the the in of customer data. with we're the some including XT
Carr Protograph. In held opportunity uniquely Prognomics, panel customers different Weill use of power enthusiasm types unbiased KOL of Steve was Cornell Ma enable, meeting Broad and for had Proteograph Philip suite possible a which of representing Mason Medical. Wisconsin, This XT assay where four the the to and of Chris MIT and the of and product included strong Kuhn June, These not applications event Josh investors what the and before. customer showcased of will from University of kit the proteomics Harvard, Institute researchers their hear we on of
unbiased has in way. Dr. X,XXX during the utilized publish the new of Orbitrap professor basis proteins proteomics. This identified physiology, at on of longitudinal the an of are flight. and in the plans Orbitrap of biophysics, and Medicine, function astronauts Astral of Weill post-flight of genomics, part results spaceflight computational the Chris Dr. in plasma Mason, identification study his who up of results XT combination these a combination in regulated Proteograph his Mason These formed samples XT over and of pre-flight Cornell is performance for Astral unbiased neuroscience of and study and biomarkers a astronaut seven and change the the Proteograph step demonstrate broader space the multi-omic for down as that impact physiology. to the
difficult similar yet previously to of flexibility the than the complex Proteograph another in was plasma June, pre-print in long-term showcases lab. in Proteograph confident shows expression protein of analyze highly enables of and range Product the or tissue such researchers opportunity novel been paper applications example exemplified type has as another University product to This differentiated In types muscle. at the by and This dynamic published proteomic the sample was This the wide Suite beyond skeletal biofluid Proteograph and a power power us. our ahead bioRxiv that insights. provide provides suite ever of the samples suite of we're tissue access. product And of Auburn levels that paper plasma has to analysis how the
domain, That to are will which our challenging third-party we actions the impacting environment. we by said, adoption, taking begin of acquisition amplified macro publications. data some data that a we're headwinds pace public the temporary customer have until and more the in accelerate confident We're commercial have
streamline reduce our our across efforts, As we areas. taken to organization our to we continue headcount development these business have action market
the match While it team, better goodbye easy of of to organization with to will is burn valued our never rightsizing revenue. our cash say the members our
our the dedication every the for work Seer the of of the boundaries With day to of commercial bring in team all proteomics. these to hard Omics changes, single technology, phase we're next globally. unlocking I Proteo. our while strategy possible preserving opportunities, truly the vision the our power their what's pushing that in I our against of and ability execute have thank help to believe realize the we labs to and want employees to
call turn David. With that, now will I over to the
